$0.7992
-0.014-1.72%
Last update: Nov 12, 12:20 PM
Phio Pharmaceuticals Corp
PHIONASDAQ
Phio Pharmaceuticals fell 48.5% from $1.58 to $0.81, behind the S&P 500's +11.2%. Its worst day was Feb 18 (−21.1%), and its low came Nov 5 at $0.80.
Nov 12, 2025 – Nov 10, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-0.44 beat the $-0.44 estimate on $0.00 revenue.
−9.1% · S&P 500 0.0%
Phio Pharmaceuticals shares fell 13.7%, while the S&P 500 fell 0.3%.
Story events cover the past 12 months · Times ET
−13.7% · S&P 500 −0.3%
Phio Pharmaceuticals closed at its highest level of the year, 4.4% above where the year started.
+35.2%, the year's best day · S&P 500 +0.1%
EPS of $-0.15 beat the $-0.42 estimate on $0.00 revenue.
−0.9% · S&P 500 −1.3%
EPS of $-0.34 missed the $-0.23 estimate on $0.00 revenue.
−6.1% · S&P 500 +0.8%
The company has received multiple favorable patent actions encompassing three notices of allowance and one grant decision to further strengthen Phio’s global intellectual property portfolio in the United States,
−13.6% · S&P 500 +0.4%
EPS of $-0.36 beat the $-0.36 estimate on $0.00 revenue.
−1.9% · S&P 500 +0.6%
EPS of $-0.36 beat the $-0.36 estimate on $0.00 revenue.
+0.2% · S&P 500 +0.3%
Where it ended: a close of $0.81 on Nov 10, 2026. Up next: Q4 2026 earnings on Mar 4, 2027 (EPS est. $-0.39).
Nothing in the past 12 months.
All PHIO analyst actionsNothing in the past 12 months.
All PHIO dividend historyReplay the year: the line draws itself and stops at each of the 8 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for PHIO and SPY from Benzinga historical bars. Not investment advice.
